Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orziloben Phase 2a in IFALD
NCT05919680Phase 2Recruiting
- Sponsor
- NorthSea Therapeutics
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SEFA-6179 in intestinal failure-associated liver disease (IFALD), sponsored by NorthSea Therapeutics. Started Jan 2024; status: recruiting.
02
Drugs
SEFA-6179
03
Conditions
intestinal failure-associated liver disease (IFALD)
Beyond the preview
Go deeper on NCT05919680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919680.